Menopausal Hormone Therapy for Bone Health Reassessed in Indian Position Paper

A position paper published in Archives of Osteoporosis argues that menopausal hormone therapy deserves renewed attention as a skeletal protection strategy for Indian women, revisiting decades of evidence on the treatment’s benefits and risks. The paper, published on 27 October 2026, was authored by a large group of Indian endocrinologists and bone health specialists led by Nupoor Vaghasia and Ambrish Mithal.

The authors’ central premise rests on the biology of menopause itself. Menopause is characterized by a rapid decline in estrogen exposure, which drives accelerated bone loss on top of the gradual age-related decline in bone mass. The paper notes this process is particularly relevant in India, where women experience menopause earlier than Western populations, a difference the authors say increases lifetime fracture risk.

According to the position paper, menopausal hormone therapy has been evaluated extensively over the years for skeletal health, with consistent evidence demonstrating preservation of bone mineral density and a reduction in vertebral and hip fractures. The authors emphasize that these benefits are seen especially when therapy is initiated early after menopause, a timing consideration that shapes much of the clinical positioning discussed in the paper.

The paper also traces the controversy that reshaped hormone therapy practice worldwide. Concerns about cardiovascular safety and breast cancer risk arose following the Women’s Health Initiative, a large trial whose findings led to a marked decline in the use of menopausal hormone therapy. The authors write that subsequent analyses of the evidence have supported a more favorable benefit–risk profile in appropriately selected younger postmenopausal women, a reinterpretation that underpins their call to revisit the therapy’s role.

On the basis of this accumulated evidence, the position paper concludes that individualized menopausal hormone therapy can improve skeletal outcomes while also benefiting menopausal symptoms and overall quality of life. The review is explicitly framed around the Indian context, aiming to clarify how the therapy should be positioned clinically in a population where earlier menopause may amplify the skeletal consequences of estrogen decline. As a position paper rather than a new clinical trial, it synthesizes existing evidence and expert consensus rather than reporting fresh experimental results, and its recommendations reflect the authors’ assessment of how current evidence applies to Indian clinical practice in 2026.

Subject of Research: The role of menopausal hormone therapy in preserving bone health and reducing fracture risk in Indian postmenopausal women.

Article Title: Revisiting menopausal hormone therapy for bone health: evidence, controversies, and clinical positioning in India in 2026

Article References: Vaghasia, N., Nagendra, L., Kapoor, N., Maldar, A., Baro, A., Bhandarkar, A., Joshi, A., Ghosh, A., Monteiro, A. S., Joseph, A., Mishra, I., Agarwal, K., Cherian, K. E., Tandon, N., Kaur, P., John, R., Shetty, S., Das, S., Bhadada, S., … Mithal, A. (2026). Revisiting menopausal hormone therapy for bone health: evidence, controversies, and clinical positioning in India in 2026. Archives of Osteoporosis, 21(1), Article 152. https://doi.org/10.1007/s11657-026-01792-9

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01792-9

Keywords: menopausal hormone therapy, bone health, osteoporosis, India, estrogen decline, fracture risk, bone mineral density, Women's Health Initiative, postmenopausal women, position paper, Revisiting, menopausal